Extracorporeal photopheresis and interferon-α in advanced cutaneous T-cell lymphoma

Lancet

Volumn 350, Issue 9070, 1997, Pages 32-33

  Dippel, E ^a   Schrag, H ^a   Goerdt, S ^b   Orfanos, C E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; CORTICOSTEROID; PSORALEN;

ADVANCED CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; PUVA; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

EID: 0030927592     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(05)66242-3     Document Type: Article

References (5)

1. Lorincz AL. Cutaneous T-cell lymphoma (mycosis fungoides). Lancet 1996; 347: 781-76.
2. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extra-corporeal photochemotherapy. N Engl J Med 1987; 316: 297-303.
3. Armus S, Keyes B, Catrill C. Photopheresis for the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1990; 23: 898-902.
4. Zic J, Arzubiaga C, Salhany KE, et al. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Acad Dermatol 1992; 27: 729-36.
5. Bunn PA, Ihde DC, Foon KA. The role of recombinant Interferon alpha-2a in the therapy of cutaneous T-cell lymphoma. Cancer 1986; 57: 1689-95.